"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Microsoft Retail Management System (RMS) point of sale AndersenIQ Integration provides a simple solution for retailers selling Andersen windows and doors products. From within Microsoft RMS point of ...

Zenas BioPharma (NASDAQ:ZBIO) shares surged 80% on Monday following the release of highly encouraging Phase 2 results from ...

Zenas BioPharma shares jumped in premarket trading after the company reported highly positive trial data for its multiple-sclerosis treatment. Shares traded over 59% higher ahead of the morning bell ...

Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in ...

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label ...

eBook The State of AI in Customer Experience 2025 How AI, human talent and unified platforms are driving up to 20% higher customer satisfaction and measurable ROI. Read now Guide Getting Started with ...

Microsoft announced late last week that it is now offering its Rights Management Service (RMS) commercially, including for premises-based installations. RMS reached the "general availability" release ...

Microsoft group program manager Dan Plastina said "We're thrilled that Nitro released its newest integration with Microsoft RMS in their flagship desktop PDF product, Nitro Pro. "Nitro Pro with RMS ...

Multiple Sclerosis (MS) is an autoimmune, inflammatory condition of the central nervous system. Relapsing MS (formerly known as Relapsing Remitting MS) is the most common form and constitutes ...

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...